Merck Serono to Collaborate with The Institute of Cancer Research, London, and Wellcome Trust to Co-Develop Anti-Cancer Drugs
* Joint program to develop drug candidates for the treatment of different forms of cancer
* Collaboration will be funded by Merck Serono and the Wellcome Trust
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Serono, the biopharmaceutical division of Merck, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, today announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.
The collaboration will be jointly funded by Merck Serono and the Wellcome Trust. The existing drug discovery program at the ICR is supported by a Wellcome Trust Seeding Drug Discovery Award.
In a joint effort, a team led by Dr. Chris Lord and Professor Alan Ashworth at the ICR and a research group at Merck Serono will aim to progress chemical compounds that have emerged from both organizations’ tankyrase inhibitor programs towards clinical development. At the end of the collaboration period, Merck Serono will take over full responsibility for the selected clinical development candidate, with the goal of bringing a new cancer therapeutic drug to patients.
Dr. Chris Lord, Team Leader in the Division of Breast Cancer Research at The Institute of Cancer Research, London, said: “Tankyrase inhibitors provide a unique opportunity to target one of the most common characteristics of cancer cells - their dependency on the so-called ‘Wnt signaling’ pathway. Both Merck Serono and the group at the ICR have already made notable progress in developing tankyrase inhibitors. Working with Merck Serono will allow us to jointly accelerate our program with the aim to ultimately make tankyrase inhibitors available to cancer patients.”
“We are delighted to work together with Dr. Chris Lord and Professor Alan Ashworth. With this partnership, we aim to harness the already well advanced tankyrase programs at both ICR and Merck Serono and hope to ultimately translate these in to novel treatment options for cancer patients. We will build on a joint compound base of potent tankyrase inhibitors and will leverage both sites’ scientific knowledge about the ‘Wnt pathway’ that plays a major role in signal transduction for tumor growth”, said Dr. Andree Blaukat, Head of the Translational Innovation Platform Oncology at Merck Serono. “The interest of the Wellcome Trust shows its belief in our researchers’ scientific data. It also shows the importance of academia-industry collaboration models in pharmaceutical development to progress the most promising investigational compounds into clinics with the aim of bringing them to patients.”
“This agreement highlights the importance of translational funding, such as the awards provided under the Seeding Drug Discovery scheme, to reduce the risk of drug discovery programs so that they become attractive to partners who have the ability to bring a product to market”, said Dr. Ted Bianco, Director of Innovations at the Wellcome Trust. “We welcome the strategic collaboration with Merck Serono, which brings together a world-leading academic drug discovery group, and an industry partner with such a strong commitment to oncology, to give the program the best possible chances of success.”
Some of the most promising advances in cancer research have been small-molecule inhibitors which block the activity of members of the poly (ADP-ribose) polymerase (PARP) enzyme family, which includes the enzyme tankyrase.1
Under the terms of the agreement, Merck Serono will make milestone payments based on achieving regulatory and sales goals plus royalty payments on net sales of future products discovered or developed under the agreement.
References
1. J.L. Riffell et al, Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012 Dec;11(12):923-36. doi: 10.1038/nrd3868
About the Wellcome Trust
The Wellcome Trust is the world’s second-highest spending charitable foundation, dedicated to achieving extraordinary improvements in human and animal health. We support bright minds in biomedical research and the medical humanities, including public engagement, education and the application of research to improve health. We are independent of both political and commercial interests. www.wellcome.ac.uk
About The Institute of Cancer Research, London
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR’s mission is to make the discoveries that defeat cancer. For more information visit www.icr.ac.uk
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono. Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology. For more information, please visit www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.
Contacts
Merck Serono
Andrea Marquart, +49 6151 72-6517
Help employers find you! Check out all the jobs and post your resume.
